emerald lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. virginia kaklamani
Published 1 year ago • 496 plays • Length 17:11Download video MP4
Download video MP3
Similar videos
-
16:10
emerald study lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. aditya bardia
-
3:32
the emerald trial | virginia kaklamani, md
-
1:01
what emerald phase iii trial could mean for breast cancer patients | virginia kaklamani, md
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
3:03
discovery and history of platinum
-
38:07
a dummies guide to variant histological differentiation in bladder cancer
-
20:37
gs2-02: "elacestrant, an oral selective estrogen receptor degrader (serd), vs investigator’s..."
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
1:16
dr. tolaney on platinum-based therapy in neoadjuvant setting of tnbc
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
1:10
dr. hamilton on the fda approval of tucatinib in her2 breast cancer
-
1:47
an overview of the ma17r trial in breast cancer
-
1:35
urothelial carcinoma: apatorsen plus docetaxel does not provide significant value
-
0:50
the addition of platinum compounds to standard chemotherapy for breast cancer patients
-
1:23
cdh1-mutated clinically advanced urothelial bladder cancer: real-world clinical outcome study
-
1:29
the predictive value of treatment response after neoadjuvant therapy
-
4:37
metabolic adaptations to targeted therapy in flt3 mutated acute myeloid leukaemia
-
2:13
case 3: mutational patterns in bladder cancer
-
1:51
ameera-3: serd for er her2- breast cancer
-
1:29
a case of a surprising metastasis